A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

July 9, 2014

Primary Completion Date

June 27, 2016

Study Completion Date

December 31, 2027

Conditions
Prostatic NeoplasmsMetastatic Castration-Resistant Prostate Cancer
Interventions
DRUG

Abiraterone Acetate

Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).

DRUG

Prednisone

Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).

DRUG

JNJ-56021927

Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).

Trial Locations (7)

Unknown

Los Angeles

San Francisco

Houston

Vancouver

Montreal

Rotterdam

Sutton

Sponsors
All Listed Sponsors
lead

Aragon Pharmaceuticals, Inc.

INDUSTRY